|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2003
Longitudinal changes in the nature, severity and frequency of COPD exacerbations
Academic Unit of Respiratory Medicine, St.Bartholomew's and Royal London School of Medicine and Dentistry, London, UK.
CORRESPONDENCE: J.A. Wedzicha, Academic Unit of Respiratory Medicine, Dominion House, St. Bartholomew's Hospital, London, EC1A 7BE, UK. Fax: 44 2076018616. E-mail: j.a.wedzicha@gmul.ac.uk
Keywords: chronic obstructive pulmonary disease, cohort studies, exacerbations
Received: April 7, 2003
Accepted September 3, 2003
This study was supported by the British Lung Foundation and GlaxoSmithKline.
Exacerbations are an important feature and outcome measure in chronic obstructive pulmonary disease (COPD), but little is known about changes in their severity, recovery, symptom composition or frequency over time.
In this study 132 patients (91 male; median age 68.4 yrs and median forced expiratory volume in one second (FEV1) 38.4% predicted) recorded daily symptoms and morning peak expiratory flow.
Patients were monitored for a median of 918 days and 1,111 exacerbations were identified. Patients with severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) category III, n=38) had an annual exacerbation frequency of 3.43·yr–1, 0.75·yr–1 higher than those with moderate COPD (GOLD II, n=94). Exacerbation frequency did not change significantly during the study. At exacerbation onset, symptom count increased to 2.23, relative to a baseline of 0.36 set 8–14 days previously, and this increase rose by 0.05·yr–1. Recovery to baseline levels in symptoms and FEV1 took longer (0.32 and 0.55 days·yr–1). Sputum purulence at exacerbation became more prevalent over time by 4.1%·yr–1 from an initial value of 17%.
The results of this study suggest that over time, individual patients have more symptoms during exacerbations, with an increased chance of sputum purulence and longer recovery times.
This article has been cited by other articles:
|
|
 |
|
  M. M. de Oca, C. Talamo, R. J. Halbert, R. Perez-Padilla, M. V. Lopez, A. Muino, J. R. B. Jardim, G. Valdivia, J. Pertuze, D. Moreno, et al. Frequency of Self-Reported COPD Exacerbation and Airflow Obstruction in Five Latin American Cities: The Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) Study Chest, July 1, 2009; 136(1): 71 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Makris, N. Tzanakis, A. Damianaki, E. Ntaoukakis, E. Neofytou, M. Zervou, N. M. Siafakas, and E. G. Tzortzaki Microsatellite DNA instability and COPD exacerbations Eur. Respir. J., September 1, 2008; 32(3): 612 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Makris, S. Lazarou, M. Alexandrakis, T. V. Kourelis, N. Tzanakis, D. Kyriakou, and K. I. Gourgoulianis Tc2 Response at the Onset of COPD Exacerbations Chest, September 1, 2008; 134(3): 483 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Abusriwil and R. A. Stockley The Interaction of Host and Pathogen Factors in Chronic Obstructive Pulmonary Disease Exacerbations and Their Role in Tissue Damage Proceedings of the ATS, December 1, 2007; 4(8): 611 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sykes, P. Mallia, and S. L. Johnston Diagnosis of Pathogens in Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 642 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Martinez Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Young, R. Hopkins, and T. E. Eaton Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes Eur. Respir. J., October 1, 2007; 30(4): 616 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gunen, S. S. Hacievliyagil, O. Yetkin, G. Gulbas, L. C. Mutlu, and E. In The role of nebulised budesonide in the treatment of exacerbations of COPD Eur. Respir. J., April 1, 2007; 29(4): 660 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Wang, J.-M. Lin, C.-Y. Li, L.-T. Lee, Y.-L. Guo, and F.-C. Sung Prevalence and Risks of Chronic Airway Obstruction: A Population Cohort Study in Taiwan Chest, March 1, 2007; 131(3): 705 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Wood, H. Powell, T. Grissell, T. T.D. Nguyen, D. Shafren, M. Hensley, and P. G. Gibson Persistent Airway Obstruction After Virus Infection Is Not Associated With Airway Inflammation Chest, February 1, 2007; 131(2): 415 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Mannino, M. M. Reichert, and K. J. Davis Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 292 - 292. [Full Text] [PDF]
|
|
|
|
|
|
N. Takabatake, Y. Shibata, S. Abe, T. Wada, J.-i. Machiya, A. Igarashi, Y. Tokairin, G. Ji, H. Sato, M. Sata, et al. A Single Nucleotide Polymorphism in the CCL1 Gene Predicts Acute Exacerbations in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 875 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mallia and S. L. Johnston How viral infections cause exacerbation of airway diseases. Chest, October 1, 2006; 130(4): 1203 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Mannino and K J Davis Lung function decline and outcomes in an elderly population Thorax, June 1, 2006; 61(6): 472 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wedzicha and T. Wilkinson Impact of Chronic Obstructive Pulmonary Disease Exacerbations on Patients and Payers Proceedings of the ATS, May 1, 2006; 3(3): 218 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. A. Wilkinson, J. R. Hurst, W. R. Perera, M. Wilks, G. C. Donaldson, and J. A. Wedzicha Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD. Chest, February 1, 2006; 129(2): 317 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G C Donaldson and J A Wedzicha COPD exacerbations {middle dot} 1: Epidemiology Thorax, February 1, 2006; 61(2): 164 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Vestbo and J C Hogg Convergence of the epidemiology and pathology of COPD Thorax, January 1, 2006; 61(1): 86 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mallia and S. L. Johnston Mechanisms and Experimental Models of Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, November 1, 2005; 2(4): 361 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J J Soler-Cataluna, M A Martinez-Garcia, P Roman Sanchez, E Salcedo, M Navarro, and R Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax, November 1, 2005; 60(11): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, and for the COSMIC (COPD and Seretide: a Multi-Center Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial Thorax, June 1, 2005; 60(6): 480 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E M Drost, K M Skwarski, J Sauleda, N Soler, J Roca, A Agusti, and W MacNee Oxidative stress and airway inflammation in severe exacerbations of COPD Thorax, April 1, 2005; 60(4): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lode, J. Eller, A. Linnhoff, M. Ioanas, and the Evaluation of Therapy-Free Interval in COPD Pa Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval Eur. Respir. J., December 1, 2004; 24(6): 947 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J R Hurst and J A Wedzicha Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation Postgrad. Med. J., September 1, 2004; 80(947): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.J. Sterk Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1 Eur. Respir. J., April 1, 2004; 23(4): 497 - 498. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |